

OUTCOMES  
BEYOND  
PERFORMANCE }

# HERMES IMPACT OPPORTUNITIES FUND

Quarterly Impact Report

Hermes Investment Management  
Q3 2018


For professional investors only

[www.hermes-investment.com](http://www.hermes-investment.com)

  
**HERMES**  
INVESTMENT MANAGEMENT

The Hermes Impact Opportunities Fund is a high-conviction global equity strategy with a bold objective. It aims to generate long-term outperformance by investing in companies succeeding in their core purpose: to generate value by creating positive and sustainable change that addresses the underserved needs of society and the environment. In this way, it focuses on tomorrow's leading companies, today.

## EXPOSURE BY IMPACT THEME



Source: Hermes as at 30 September 2018.

This document does not constitute a solicitation or offer to any person to buy or sell any related securities or financial instruments. The value of investments and income from them may go down as well as up, and you may not get back the original amount invested. Past performance is not a reliable indicator of future results and targets are not guaranteed.




# THEMATIC FOCUS: HEALTH AND WELLBEING

Improving life expectancy and quality



## 1 Worldwide, life expectancy is on the rise




## 2 But we are far from an all-clear diagnosis for global health and wellbeing

- Cancer survival rates have increased by 25% overall – but there has been little or no progress in effective treatments for incidences affecting the pancreas, lung, oesophagus or brain
- Over-use of antibiotics – by humans and in livestock production – promotes antimicrobial resistance that could render this basic but effective medication useless
- Access to quality healthcare is unequal within and among countries, and national health systems are struggling with rising costs
- Certain unethical behaviours from some companies persist within the healthcare sector and include excessive pricing, aggressive marketing and biases in research publication

### In many aspects of daily life, we are not helping the cause

Researchers are finding more evidence that many types of cancer are primarily caused by external risk factors – such as smoking, diet and nutrition, alcohol consumption, air pollution and exposure to carcinogens – rather than bad luck: random mutations during DNA replication in non-cancerous cells

### Share of cancer deaths attributed to risk factors, 2016



Source: IHME, Global Burden of Disease, as at 2017.

### 3 To help overcome these challenges, we invest in companies creating the following impacts



#### MEDICAL INNOVATIONS that radically change outcomes for patients

- Accelerating **genome sequencing**, potentially enabling further breakthroughs in gene and cell therapy, at ever-lower costs
- Alleviating heavy medical burdens, like diabetes, through innovative and **widely accessible medicines**
- Enabling **research validation and progress** by consistently providing high-quality antibodies, and plasma, the building block of biological drugs

#### OUR EXPOSURE

Medical-technology company **LivaNova** is recognised as a leader in cardiac-surgery solutions, supplying heart-lung machines and heart-valve prostheses. The London-headquartered company also pioneered the vagus nerve stimulation system for treating heart failure, drug-resistant epilepsy and, most recently, treatment-resistant depression. Depression is the leading cause of disability worldwide and the second leading cause of death among 15-19 year old girls.

#### DISEASE PREVENTION and early diagnosis



- **Cleanliness and hygiene** in healthcare operations to prevent the spread of disease and infection
- More **powerful diagnostics, testing and research** laboratories
- Improved infrastructure to **reduce road fatalities**, the ninth-largest cause of death worldwide

#### OUR EXPOSURE

Supplier of surgical and diagnostics products for the treatment of cataracts and diabetic retinopathy, **Carl Zeiss** plays an important role in alleviating the burden of preventable sight loss. Cataracts are responsible for 51% of the blindness in the world and diabetic retinopathy – a cause of blindness set to increase along with the incidence of diabetes – is on the World Health Organisation's priority list of eye conditions which can be partially prevented and treated.



#### BROADENING ACCESS to cost-effective healthcare among underserved populations

- Expanding the coverage of **generic and biosimilar medicines**, which are proven treatments and do not require lengthy clinical tests
- Provision of **affordable healthcare** services, including through digital channels

#### OUR EXPOSURE

With the greatest share of the next-generation sequencing market, **Illumina** has been instrumental in driving down costs and is credited for breaking the \$1000 human-genome-sequencing barrier. Its latest technologies aim to lower costs further, potentially increasing the volumes and speed of sequencing and thereby enabling progress in the fields of precision medicine and research into genetic deficiencies.

#### Improving outcomes in NEGLECTED AREAS



- Targeting **tropical diseases** in developing countries and building resistance to pandemics
- Treating **rare diseases**, which can affect one in 15 people – or 400m worldwide – and are often genetically based, chronic and potentially life threatening

#### OUR EXPOSURE

Biotechnology company **Emergent Biosolutions** focuses on threats to public health and has a promising pipeline of treatments – particularly those targeting emerging infectious diseases. The company's products help governments improve their capacity to respond to and contain those risks that could otherwise lead to pandemics. These include the development of vaccines and treatments for the Zika, Chikungunya, influenza A, Ebola and HIV viruses.



## REVOLUTIONARY PROMISE: NEXT-GENERATION SEQUENCING

Advanced genetic sequencing is believed to be capable of fulfilling one of the greatest promises of future medicine. It aims for nothing less than to decipher the human genome – our organism’s complete set of genetic information – thereby supporting breakthroughs in medical research and treatment. As such, companies leading in this field are firmly aligned with our Health and Wellbeing impact theme.

Since a human genome was sequenced for the first time in 2003, researchers have gained unprecedented insights into genetic factors that cause or influence disease. But much more can be achieved. Next-generation sequencing (NGS) is able to handle much higher throughput volume, enabling scientists to progress from sequencing one DNA fragment at a time to millions in a single run.<sup>1</sup>

The wealth of genomic data that NGS provides could accelerate progress in precision medicine: treatments tailored to each individual. Researchers hope that it will eventually help correct genetic deficiencies linked to several diseases targeted by the third Sustainable Development Goal – Good Health and Well-Being – ranging from diabetes to cancer. To indicate the magnitude of its potential impact, we note that genetic diseases account for 45-51% of deaths in neonatal intensive care units and 60% of end-of-life admissions.<sup>2</sup>

The increasing prominence of genetic sequencing is intrinsically linked to its affordability: as the process becomes less expensive, more genes can be sequenced and volumes of data generated, yielding deeper insights. The cost of genetic sequencing has tumbled dramatically in defiance of Moore’s law, the observation that computing power doubles and price halves every two years.

Indeed, the cost of sequencing the first human genome, achieved by the Human Genome Project in 2003, is estimated to have been anywhere between \$500m and \$1bn.<sup>3</sup> Researchers have now broken the \$1000 genome barrier, widely considered to be the threshold at which NGS will become commonplace in medicine (see figure 1).

Genetic sequencing, once an expensive tool reserved for academic and government research, is now rapidly beginning to inform clinical practices and even the consumer market. It is likely to reshape medicine as we know it.


We believe that two companies we invest in, Illumina and Qiagen, generate impacts that support the delivery of targets within the SDG of Good Health and Well-Being:



**SDG sub-target 3.2:** By 2030, end preventable deaths of newborns and children under five years of age, with all countries aiming to reduce neonatal mortality to at least as low as 12 per 1000 live births and mortality in under-five-year-olds to at least as low as 25 per 1000 live births

**SDG sub-target 3.4:** By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment, and promote mental health and well-being

Figure 1. Lawbreakers in laboratories: the cost of sequencing genomes declined rapidly in the past decade<sup>4</sup>



Source: National Human Genome Research Institute as at July 2017.

### Illumina

Commanding the vast majority of market share in the NGS market, Illumina has been the key contributor to driving down the cost of genetic sequencing. Indeed, according to the San Diego-based company, more than 90% of the world’s sequencing data has been generated by using Illumina technology.<sup>4</sup>

Notably, Illumina is credited for having broken the \$1000 genome-sequencing barrier. But the company is aiming to lower costs further. With NovaSeq, the most powerful sequencer that Illumina has launched to date, the business seeks to show that a genome can be sequenced for \$100 – a cost that is cheaper than most x-rays.<sup>5</sup> The sequencer’s launch in 2017 has surpassed expectation to date and catapulted Illumina to record quarterly revenue this year.

Illumina’s other investments include Grail, which aims to create a very early stage and universal cancer test, and Helix, a consumer genomics marketplace with a mission to democratise access to genetic sequencing.

### Qiagen

While Illumina is undoubtedly the giant in the NGS market, boasting a broad range of instruments for whole-of-genome sequencing, Qiagen has thrived in a specialist niche: expanding access to NGS for the smaller diagnostic and clinical research markets.

The German company’s GeneReader solution, launched in 2015, focuses on oncology applications in these markets. Since then, Qiagen has targeted further markets: this year, the company announced its foray into the analysis of hereditary disease, and it has applications in the pipeline that range from prenatal testing to infectious-disease genotyping.

<sup>1</sup> "Key differences between next-generation sequencing and Sanger sequencing," published by Illumina. Accessed October 2018.

<sup>2</sup> "Unlocking the power of the genome," by Samad, S. Presentation to the William Blair Growth stock conference on 13 June 2018.

<sup>3</sup> "The cost of sequencing a human genome," published by the National Human Genome Research Institute. Last updated 6 July 2016.

<sup>4</sup> According to Illumina calculations in 2015.

<sup>5</sup> "The secret genomic revolution," by Gillian Tett. Published in the FT Magazine on 17 March 2017.

### Hermes Investment Management

We are an asset manager with a difference. We believe that, while our primary purpose is to help savers and beneficiaries by providing world class active investment management and stewardship services, our role goes further. We believe we have a duty to deliver holistic returns – outcomes for our clients that go far beyond the financial – and consider the impact our decisions have on society, the environment and the wider world.

Our goal is to help people invest better, retire better and create a better society for all.

### Our investment solutions include:

High active share equities, private markets, credit and responsible investment advisory services.

For more information, visit [www.hermes-investment.com](http://www.hermes-investment.com) or connect with us on social media:   

**Federated** | HERMES IS A FEDERATED INVESTORS COMPANY.

**For professional investors only.** This document does not constitute a solicitation or offer to any person to buy or sell any related securities or financial instruments; nor does it constitute an offer to purchase securities to any person in the United States or to any US Person as such term is defined under the US Securities Exchange Act of 1933. It pays no regard to the investment objectives or financial needs of any recipient. No action should be taken or omitted to be taken based on this document. Tax treatment depends on personal circumstances and may change. This document is not advice on legal, taxation or investment matters so investors must rely on their own examination of such matters or seek advice. Before making any investment (new or continuous), please consult a professional and/or investment adviser as to its suitability. This document is not investment research and is available to any investment firm wishing to receive it.

**Any opinions expressed may change. The value of investments and income from them may go down as well as up, and you may not get back the original amount invested. Any investments overseas may be affected by currency exchange rates. Past performance is not a reliable indicator of future results and targets are not guaranteed.** All figures, unless otherwise indicated, are sourced from Hermes. For more information please read any relevant Offering Documents or contact Hermes.

**UCITS funds:** Further information on investment products and any associated risks can be found in the Fund's Key Investor Information Document ("KIID"), the Prospectus, the articles of association and the annual and semi-annual reports. In the case of any inconsistency between the descriptions or terms in this document and the Prospectus, the Prospectus shall prevail. These documents are available free of charge at Hermes Investment Funds plc, Georges Court, 54-62 Townsend Street, Dublin 2, Ireland, [www.hermes-investment.com](http://www.hermes-investment.com); and at its representative in Switzerland (ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zurich, [www.acolin.ch](http://www.acolin.ch)). The Paying agent in Switzerland is NPB Neue Privat Bank AG, Limmatquai 1, CH-8001 Zürich. HIML is the investment manager and promoter of Hermes Investment Funds plc ("HIF") – an open-ended investment company with variable capital and with segregated liability between its sub-funds – incorporated in Ireland. Authorised by the Central Bank of Ireland and recognised by the Financial Conduct Authority.

The main entities operating under the name Hermes are: Hermes Investment Management Limited ("HIML"); Hermes Alternative Investment Management Limited ("HAIML"); Hermes European Equities Limited ("HEEL"); Hermes Real Estate Investment Management Limited ("HREIML"); Hermes Equity Ownership Limited ("HEOS"); Hermes GPE LLP ("Hermes GPE"); Hermes GPE (USA) Inc ("Hermes GPE USA") and Hermes GPE (Singapore) Pte. Limited ("HGPE Singapore"). All are separately authorised and regulated by the Financial Conduct Authority except for HREIML, HEOS, Hermes GPE USA and HGPE Singapore. HIML currently carries on all regulated activities associated with HREIML, HAIML, HEEL, Hermes GPE and Hermes GPE USA are all registered investment advisers with the United States Securities and Exchange Commission ("SEC"). HGPE Singapore is regulated by the Monetary Authority of Singapore.

Issued and approved by Hermes Investment Management Limited which is authorised and regulated by the Financial Conduct Authority. Registered address: Sixth Floor, 150 Cheapside, London EC2V 6ET. Telephone calls will be recorded for training and monitoring purposes. Potential investors in the United Kingdom are advised that compensation will not be available under the United Kingdom Financial Services Compensation Scheme.

In Singapore this document and the information contained herein shall not constitute an offer to sell or the solicitation of any offer to buy which may only be made at the time a qualified offeree received a Hermes Investment Funds plc prospectus, as supplemented with the global supplement, the relevant Fund supplement, and the relevant Singapore supplement (the Prospectus) describing the offering and the related subscription agreement. In the case of any inconsistency between the descriptions or terms in this document and the prospectus, the prospectus shall control. Securities shall not be offered or sold in any jurisdiction in which such offer solicitation or sale would be unlawful until the requirements of the laws of such jurisdiction have been satisfied. For the avoidance of doubt, this document has not been prepared for delivery to and review by persons to whom offer any units in a scheme is to be made so as to assist them in making an investment decision. The document & the information contained herein shall not constitute part of any information memorandum. Without prejudice to anything contained herein, neither this document or any copy of it may be taken or transmitted into any country where the distribution or dissemination is prohibited. This document is being furnished on a confidential basis and solely for information and may not be reproduced, disclosed or distributed to any other person. This document has not been reviewed by the Monetary Authority of Singapore.

In Spain the information hereby contained referred to a sub-fund (the Sub-fund) of Hermes Investment Funds plc (the Company), a collective investment scheme duly registered with the Spanish Securities Market Commission (CNMV) under number 1394 ([www.cnmv.es](http://www.cnmv.es)), where it may be consulted the updated list of the authorised distributors of the Company in Spain (the Spanish Distributors). This document only contains brief information on the Sub-Fund and does not disclose all of the risks and other significant aspects relevant to a potential investment in the Sub-Fund. Any investment decision must be based solely on the basis of a careful consideration and understanding of all information contained in the latest Company's prospectus, simplified prospectus or key investor information document (KIID), when implemented and the latest half-yearly and audited yearly reports. The Spanish Distributors must provide to each investor, prior to subscribing the shares of the Sub-fund, a copy translated into Spanish of the simplified prospectus or KIID, when implemented, and the latest published economic report prior to subscribing shares. In addition, a copy of the report on the planned types of marketing in Spain must be provided using the form published on the CNMV website. All mandatory official documentation shall be available through the Spanish Distributors, in hard copy or by electronic means, and also available upon request. These documents are also available free of charge at Hermes Investment Funds plc, Georges Court, 54-62 Townsend Street, Dublin 2, Ireland, [www.hermes-investment.com](http://www.hermes-investment.com). It is advisable to obtain further information and request professional advice before taking an investment decision. Hermes Investment Management Limited is duly passported into Spain to provide investment services in such jurisdiction on a cross-border basis and is registered for such purposes with the Spanish Securities Market Commission – Comisión Nacional del Mercado de Valores (CNMV) under number 3674. BD02565 10/18 0004884